About Merck Sharp & Dohme
Merck Sharp & Dohme is a Healthcare company based in Kenilworth (United States) founded in 1890, and was acquired by Onyx Equities in February 2023. Therapies for HIV, cancer, diabetes, and infectious diseases are developed. Merck Sharp & Dohme has completed 2 acquisitions, including EyeBio and Merck. Its website msd.com draws about 296 thousand monthly visits. Its Indian entity Msd Pharmaceuticals Private Limited reported revenue of ₹2,749 Cr. Merck Sharp & Dohme offers products and services including Vaccines, Medicines, and Clinical Trials. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Viral. Its competitors include C4 Therapeutics, Erasca and MiRagen; 3 of its 3 listed competitors have raised funding.
Company details
Merck Sharp Dohme was founded in 1890 and is headquartered in Kenilworth, United States. Operations focus on pharmaceutical development within the healthcare sector. A pipeline of therapies is maintained, including MK-1439A for HIV treatment, V184 vaccine for chikungunya virus, and V937 for breast cancer. Additional portfolios address diabetes, infectious diseases, and oncology, with research extending to various therapeutic areas.
- Headquarters Kenilworth, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website msd.com
- Social LinkedIn X Facebook Instagram YouTube
- Acquired by Onyx Equities (Feb 2023)
- Legal Name Merck & Co., Inc., Rahway, Nj, Usa
- Date of Incorporation 03 Dec, 2004
- Indian entity revenue₹2,749 Cr
FY 2025 · +35% YoY
- Indian entity net profit₹353 Cr
FY 2025 · 13% margin
- Indian entity EBITDA₹551 Cr
FY 2025 · 20% margin
- Latest Funding Round$12.03K (USD), Grant
Oct 2019
- InvestorsEuropean Union
& 2 more
- Investments & AcquisitionsEyeBio
& 1 more
- Acquired byOnyx Equities
(Feb 2023)
Associated legal entities of Merck Sharp & Dohme
Merck Sharp & Dohme operates through Msd Pharmaceuticals Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Msd Pharmaceuticals Private Limited CIN U24230DL2004PTC164459 | Active | 03 Dec 2004 | New Delhi, Delhi | ₹2,749 Cr | 1,146 | 3 | View details |
Products & Services of Merck Sharp & Dohme
Merck Sharp & Dohme offers a comprehensive portfolio of products and services, including Vaccines, Medicines, and Clinical Trials.
Products for preventing infectious diseases through immunization.
Treatments for conditions like oncology and immunology.
Platforms for testing new health solutions and innovations.
Apps and channels of Merck Sharp & Dohme
its YouTube channel MSD has 978 subscribers.
Funding Insights of Merck Sharp & Dohme
- Total Rounds 3
- Last Round Grant — $12,030
- First Round $1.59M
(Apr 2015)
- Investors Count 1
All 3 funding rounds of Merck Sharp Dohme with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2019 | $12,030 | Grant | – | – | |
| Apr 2017 | $272,141 | Grant | – | – | |
| Apr 2015 | $1.59M | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Merck Sharp & Dohme
Merck Sharp & Dohme has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include European Union, Machine Investment Group and Onyx Equities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Invests in middle market real estate opportunities, distressed debt, and special situations. | 2020 | machineinv.com | New York, United States | |
Acquires and manages under-performing commercial properties with full service platform. | 2004 | onyxequities.com | Woodbridge Township, United States |
Investor details for Merck Sharp Dohme
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Msd Pharmaceuticals Private Limited (Merck Sharp & Dohme)
Msd Pharmaceuticals Private Limited is the primary company behind Merck Sharp & Dohme. The board of Msd Pharmaceuticals Private Limited currently have 2 directors; the longest-serving is Rehan Khan Abbas, appointed in 2021. 19 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Rehan Khan Abbas DIN 02616924 | Managing Director | 07 May 2021 | 5 yrs 6 mo | Msd Pharmaceuticals Private Limited |
| Chand Berry DIN 03509437 | Whole-time director | 30 Sep 2021 | 5 yrs 1 mo | Msd Pharmaceuticals Private Limited |
People of Merck Sharp & Dohme
1248 people are tracked at Merck Sharp & Dohme (845 in leadership, 12 in board & advisors, 391 in team).
| Name | Role | Group |
|---|---|---|
Jacob Bordens | Senior Director, Enterprise Architecture | Leadership |
Kelley Brna | Vice President Operations | Leadership |
Robert Tynebor | Director | Leadership |
Jerry Timmons | Retired Associate Director Of Operations | Leadership |
Sebastian S. | Director | Leadership |
Dave Williams | EVP, Chief Information & Digital Officer | Leadership |
Hardik Chandasana | Director, Quantitative Pharmacology And Pharmacometrics | Leadership |
My Mansueto | Director | Leadership |
Edina Avdic | Associate Director-regulatory Affairs-global Labeling | Leadership |
Manshi Patel | Associate Director- Global Microbial Quality Sterility Assurance | Leadership |
Sany Hoxha | Director, Oncology Translational Science And Clinical Biomarkers | Leadership |
Ashley Wivel | Vice President, Head Of Clinical Safety And Risk Management | Leadership |
Naveed Shaik | Director, Quantitative Pharmacology And Pharmacometrics | Leadership |
Allison Shaner | Chief Of Staff, HR Manufacturing | Leadership |
Brandon Koffel | Associate Director Discovery Sourcing & Procurement - Global Clinical Supply & Analytical Labs | Leadership |
Andrea Lorena Buitrago Lozano | Associate Director, Lead Study Manager | Leadership |
Aatosh Chauhan | Executive Director, External Manufacturing Strategy & Operations At Merck | Leadership |
Renata Eiras | Executive Director, Distinguished Scientist, PDT Lead | Leadership |
Gina M. Gualtiere Mshs | Associate Director Clinical Quality Operations | Leadership |
Brendan McLaughlin | Associate Director, US Oncology Marketing, Campaign Development Lead | Leadership |
1228 more people are available in the full profile.
Complete people profiles for Merck Sharp & Dohme
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Merck Sharp & Dohme
Figures of Msd Pharmaceuticals Private Limited, the primary company behind Merck Sharp & Dohme, for FY 2025. Revenue was ₹2,749 Cr (+35% year on year). Net profit was ₹353 Cr (13% margin). EBITDA was ₹551 Cr (20% margin). Revenue has grown at a compounded annual rate of +21% over three years and +15% over five years.
- ₹2,749 CrRevenue · FY 2025 · +35% YoY
- ₹353 CrNet profit · 13% margin
- ₹551 CrEBITDA · 20% margin
- ₹13.20 CrPaid-up capital
- 1,146Employees (provident fund records)
- +21%Revenue CAGR, 3 years
- +15%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Msd Pharmaceuticals Private Limited are on its company page.
Detailed financial statements for Merck Sharp & Dohme
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Merck Sharp & Dohme
Merck Sharp & Dohme has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include EyeBio and Merck.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Therapies for ophthalmological diseases are developed to restore vision. | eyebiotech.com | London, United Kingdom | 2021 | May 2024 | $1.3B | |
T-cell antibodies are developed against hematologic and solid tumor targets. | harpoontx.com | Cambridge, United States | 2015 | Jan 2024 | $680M |
Complete acquisition details for Merck Sharp Dohme
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Merck Sharp & Dohme
6 dated milestones of Merck Sharp & Dohme across 134 years, from founding to its latest funding, stage changes and deals.
- Founded Merck Sharp & Dohme is founded.
- Funding First funding round of $1.6M.
- Funding Latest funding round, Grant, of $12K.
- Exit Acquired by Onyx Equities.
- Acquisition Acquires Merck.
- Acquisition Acquires EyeBio.
Competitors of Merck Sharp & Dohme
Merck Sharp & Dohme has 3 listed competitors in our database, 3 of them funded. They include C4 Therapeutics, Erasca and MiRagen.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. |
Detailed competitors of Merck Sharp Dohme
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Merck Sharp & Dohme
The website of Merck Sharp & Dohme (msd.com) receives about 296.3K visits a month and ranks #177,559 among all websites worldwide, #5,648 in Biotechnology and Pharmaceuticals.
- Monthly visits296.3K
▲ 10.5% vs previous month
- Unique visitors120.7K
per month
- Global rank#177,559
among all websites
- Category rank#5,648
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit2.1
- Average visit1 min 04 sec
- DevicesDesktop 40% · Mobile 60%
Websites whose visitors overlap most with Merck Sharp & Dohme. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| msd-uk.com | 100% | 7.2K | #2,764,472 | View details | |
| pfizer.com | 96% | 1.9M | #24,984 | View details | |
| astrazeneca.com | 87% | 1.3M | #48,983 | View details | |
corporativo.msdonline.com.br | corporativo.msdonline.com.br | 81% | – | ||
| merckgroup.com | 78% | 910.8K | #54,804 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 34 similar websites and full traffic analytics for Merck Sharp & Dohme
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 34 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Merck Sharp & Dohme (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Merck Sharp & Dohme
Complete news archive for Merck Sharp Dohme
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Merck Sharp & Dohme
Merck Sharp & Dohme was founded in 1890 and raised its 1st funding round 125 years after it was founded.
Merck Sharp & Dohme is headquartered in Kenilworth, United States.
The primary company behind Merck Sharp & Dohme, Msd Pharmaceuticals Private Limited, reported revenue of ₹2,749 Cr for FY 2025, up 35% year on year.
Merck Sharp Dohme was founded in 1890 and is headquartered in Kenilworth, United States. Operations focus on pharmaceutical development within the healthcare sector. A pipeline of therapies is maintained, including MK-1439A for HIV treatment, V184 vaccine for chikungunya virus, and V937 for breast cancer. Additional portfolios address diabetes, infectious diseases, and oncology, with research extending to various therapeutic areas.
Merck Sharp & Dohme's top competitors include C4 Therapeutics, Erasca and MiRagen.
Merck Sharp & Dohme offers Vaccines, Medicines, and Clinical Trials.
Merck Sharp & Dohme has 3 investors. Key investors include European Union, Machine Investment Group, and Onyx Equities.
Merck Sharp & Dohme operates through Msd Pharmaceuticals Private Limited.
Yes. Merck Sharp & Dohme was acquired by Onyx Equities in February 2023.
The legal entities of Merck Sharp & Dohme currently have 3 directors, including Satinder Jeet Kaur, Chand Berry, Rehan Khan Abbas.
The website of Merck Sharp & Dohme receives about 296 thousand visits a month and ranks #177,559 among all websites worldwide.